Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
17/06/2024 | 22:12 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:OCUL | Ocular Therapeutix Inc |
14/06/2024 | 15:03 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:OCUL | Ocular Therapeutix Inc |
13/06/2024 | 22:05 | GlobeNewswire Inc. | Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study | NASDAQ:OCUL | Ocular Therapeutix Inc |
05/06/2024 | 13:30 | GlobeNewswire Inc. | Ocular Therapeutix® to Host Investor Day on June 13, 2024 | NASDAQ:OCUL | Ocular Therapeutix Inc |
04/06/2024 | 23:28 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:OCUL | Ocular Therapeutix Inc |
04/06/2024 | 23:26 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:OCUL | Ocular Therapeutix Inc |
04/06/2024 | 22:05 | GlobeNewswire Inc. | Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:OCUL | Ocular Therapeutix Inc |
30/05/2024 | 23:17 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:OCUL | Ocular Therapeutix Inc |
07/05/2024 | 22:20 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:OCUL | Ocular Therapeutix Inc |
07/05/2024 | 22:05 | GlobeNewswire Inc. | Ocular Therapeutix™ Reports First Quarter 2024 Results | NASDAQ:OCUL | Ocular Therapeutix Inc |
07/05/2024 | 22:01 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:OCUL | Ocular Therapeutix Inc |
07/05/2024 | 02:16 | GlobeNewswire Inc. | Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:OCUL | Ocular Therapeutix Inc |
06/05/2024 | 13:30 | GlobeNewswire Inc. | Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences | NASDAQ:OCUL | Ocular Therapeutix Inc |
03/05/2024 | 13:30 | GlobeNewswire Inc. | Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 | NASDAQ:OCUL | Ocular Therapeutix Inc |
01/05/2024 | 13:30 | GlobeNewswire Inc. | Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 | NASDAQ:OCUL | Ocular Therapeutix Inc |
11/03/2024 | 21:12 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:OCUL | Ocular Therapeutix Inc |
11/03/2024 | 11:39 | IH Market News | U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher | NASDAQ:OCUL | Ocular Therapeutix Inc |
19/02/2024 | 15:00 | PR Newswire (US) | AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiviti | NASDAQ:OCUL | Ocular Therapeutix Inc |
15/02/2024 | 14:00 | GlobeNewswire Inc. | Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer | NASDAQ:OCUL | Ocular Therapeutix Inc |
15/02/2024 | 01:48 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:OCUL | Ocular Therapeutix Inc |
13/02/2024 | 13:37 | GlobeNewswire Inc. | Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD | NASDAQ:OCUL | Ocular Therapeutix Inc |
28/12/2023 | 22:17 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:OCUL | Ocular Therapeutix Inc |
18/12/2023 | 22:52 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:OCUL | Ocular Therapeutix Inc |
18/12/2023 | 22:01 | GlobeNewswire Inc. | Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | NASDAQ:OCUL | Ocular Therapeutix Inc |
14/12/2023 | 22:09 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:OCUL | Ocular Therapeutix Inc |
14/12/2023 | 04:09 | GlobeNewswire Inc. | Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock | NASDAQ:OCUL | Ocular Therapeutix Inc |
14/12/2023 | 01:07 | Dow Jones News | Stocks to Watch: Adobe, Amtech Systems, Ocular Therapeutix | NASDAQ:OCUL | Ocular Therapeutix Inc |
13/12/2023 | 22:01 | GlobeNewswire Inc. | Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock | NASDAQ:OCUL | Ocular Therapeutix Inc |
17/11/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:OCUL | Ocular Therapeutix Inc |
08/11/2023 | 14:00 | GlobeNewswire Inc. | Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences | NASDAQ:OCUL | Ocular Therapeutix Inc |